CN101578266B - 环烷基胺取代的异喹啉和异喹啉酮衍生物 - Google Patents
环烷基胺取代的异喹啉和异喹啉酮衍生物 Download PDFInfo
- Publication number
- CN101578266B CN101578266B CN2007800484652A CN200780048465A CN101578266B CN 101578266 B CN101578266 B CN 101578266B CN 2007800484652 A CN2007800484652 A CN 2007800484652A CN 200780048465 A CN200780048465 A CN 200780048465A CN 101578266 B CN101578266 B CN 101578266B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- chloro
- group
- isoquinoline
- oxygen base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *Nc(cc1)ccc1Cl Chemical compound *Nc(cc1)ccc1Cl 0.000 description 1
- CJBGRTOZVUYCOE-UHFFFAOYSA-N C=CCC(CC1)(CCC1Oc(c(Cl)c1)cc(C=CN2)c1C2=O)N Chemical compound C=CCC(CC1)(CCC1Oc(c(Cl)c1)cc(C=CN2)c1C2=O)N CJBGRTOZVUYCOE-UHFFFAOYSA-N 0.000 description 1
- GBHHLCVEBFUUQJ-UHFFFAOYSA-N CC(C)(C)S(NC(Cc1ccccc1)(CC1)CCC1Oc(cc(C=CN(Cc(cc1)ccc1OC)C1=O)c1c1)c1Cl)=O Chemical compound CC(C)(C)S(NC(Cc1ccccc1)(CC1)CCC1Oc(cc(C=CN(Cc(cc1)ccc1OC)C1=O)c1c1)c1Cl)=O GBHHLCVEBFUUQJ-UHFFFAOYSA-N 0.000 description 1
- QVSAAVKKEDIERR-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)OC(CC1)CCC1=NS(C(C)(C)C)=O Chemical compound CC(C)(C)[Si+](C)(C)OC(CC1)CCC1=NS(C(C)(C)C)=O QVSAAVKKEDIERR-UHFFFAOYSA-N 0.000 description 1
- AIHIBUPIWYHSEQ-UHFFFAOYSA-N CC1C=C(C(CN)(CC2)CCC2Oc(c(Cl)c2)cc(C=CN3)c2C3=O)C=CC1 Chemical compound CC1C=C(C(CN)(CC2)CCC2Oc(c(Cl)c2)cc(C=CN3)c2C3=O)C=CC1 AIHIBUPIWYHSEQ-UHFFFAOYSA-N 0.000 description 1
- BQOIFJMUIOCETG-UHFFFAOYSA-N COC(C(CC1)(CCC11OCCO1)c(cc1)ccc1N)=O Chemical compound COC(C(CC1)(CCC11OCCO1)c(cc1)ccc1N)=O BQOIFJMUIOCETG-UHFFFAOYSA-N 0.000 description 1
- JJKIFVWUOCEGCD-UHFFFAOYSA-N COc1ccc(C(CN)(CC2)CCC2Oc(c(Cl)c2)cc(C=CN3)c2C3=O)cc1 Chemical compound COc1ccc(C(CN)(CC2)CCC2Oc(c(Cl)c2)cc(C=CN3)c2C3=O)cc1 JJKIFVWUOCEGCD-UHFFFAOYSA-N 0.000 description 1
- IZPVDCQGUIHWGO-UHFFFAOYSA-N COc1ccc(CN(C=Cc(cc2OC(CC3)CCC3=O)c3cc2Cl)C3=O)cc1 Chemical compound COc1ccc(CN(C=Cc(cc2OC(CC3)CCC3=O)c3cc2Cl)C3=O)cc1 IZPVDCQGUIHWGO-UHFFFAOYSA-N 0.000 description 1
- MEYHERQCARSMET-UHFFFAOYSA-N Fc(c(Cl)c1)cc2c1c(OCc1ccccc1)ncc2 Chemical compound Fc(c(Cl)c1)cc2c1c(OCc1ccccc1)ncc2 MEYHERQCARSMET-UHFFFAOYSA-N 0.000 description 1
- GIGCACGDUWISGL-UHFFFAOYSA-N NC(CC1)(CCC1Oc(c(Cl)c1)cc2c1c(OCc1ccccc1)ncc2)C1CC1 Chemical compound NC(CC1)(CCC1Oc(c(Cl)c1)cc2c1c(OCc1ccccc1)ncc2)C1CC1 GIGCACGDUWISGL-UHFFFAOYSA-N 0.000 description 1
- QLBYVJQLFXDTAY-UHFFFAOYSA-N NC(CCCO)(CCC1)CCCC1Oc(c(Cl)c1)cc(C=CN2)c1C2=O Chemical compound NC(CCCO)(CCC1)CCCC1Oc(c(Cl)c1)cc(C=CN2)c1C2=O QLBYVJQLFXDTAY-UHFFFAOYSA-N 0.000 description 1
- FPCKXJVZJQTPHN-UHFFFAOYSA-N NC1(CCC(COc(c(Cl)c2)cc3c2c(OCc2ccccc2)ncc3)CC1)C1CC1 Chemical compound NC1(CCC(COc(c(Cl)c2)cc3c2c(OCc2ccccc2)ncc3)CC1)C1CC1 FPCKXJVZJQTPHN-UHFFFAOYSA-N 0.000 description 1
- UPMBVMQECHUJTD-JZDHVQPBSA-N N[C@@H](C[C@H]1CC2)C[C@H]2[C@@H]1Oc(c(Cl)c1)cc(C=CN2)c1C2=O Chemical compound N[C@@H](C[C@H]1CC2)C[C@H]2[C@@H]1Oc(c(Cl)c1)cc(C=CN2)c1C2=O UPMBVMQECHUJTD-JZDHVQPBSA-N 0.000 description 1
- ASJFJIDWHPYXNP-ZNHQWHCXSA-N N[C@@H]1C[C@H](CC2)C(COc(c(Cl)c3)cc(C=CN4)c3C4=O)[C@H]2C1 Chemical compound N[C@@H]1C[C@H](CC2)C(COc(c(Cl)c3)cc(C=CN4)c3C4=O)[C@H]2C1 ASJFJIDWHPYXNP-ZNHQWHCXSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06026897.6 | 2006-12-27 | ||
| EP06026897 | 2006-12-27 | ||
| EP060268976 | 2006-12-27 | ||
| PCT/EP2007/011169 WO2008077556A1 (en) | 2006-12-27 | 2007-12-19 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101578266A CN101578266A (zh) | 2009-11-11 |
| CN101578266B true CN101578266B (zh) | 2013-10-30 |
Family
ID=38050127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800484652A Expired - Fee Related CN101578266B (zh) | 2006-12-27 | 2007-12-19 | 环烷基胺取代的异喹啉和异喹啉酮衍生物 |
Country Status (37)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ565040A (en) | 2005-06-28 | 2010-05-28 | Sanofi Aventis | Isoquinoline derivatives as inhibitors of RHO-kinase |
| WO2007008926A1 (en) | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| JP5049970B2 (ja) | 2005-07-26 | 2012-10-17 | サノフイ | Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体 |
| KR101373535B1 (ko) | 2005-07-26 | 2014-03-12 | 사노피 | Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체 |
| WO2008036540A2 (en) | 2006-09-20 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| NZ577980A (en) | 2006-12-27 | 2012-01-12 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone derivatives |
| EP2114920A1 (en) | 2006-12-27 | 2009-11-11 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| RU2455302C2 (ru) | 2006-12-27 | 2012-07-10 | Санофи-Авентис | ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ |
| KR20090092303A (ko) | 2006-12-27 | 2009-08-31 | 사노피-아벤티스 | 사이클로알킬아민 치환된 이소퀴놀린 유도체 |
| WO2008077555A2 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinolines and their use as rho-kinase inhibitors |
| RU2468011C2 (ru) | 2006-12-27 | 2012-11-27 | Санофи-Авентис | Замещенные циклоалкиламином производные изохинолина и изохинолинона |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| HRP20131040T1 (hr) * | 2008-06-24 | 2013-12-06 | Sanofi | Bi- i policikliäśki supstituirani izokinolin i derivati izokinolina kao inhibitori rho-kinaze |
| CN102131784B (zh) | 2008-06-24 | 2014-08-27 | 赛诺菲-安万特 | 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮 |
| PT2313374E (pt) * | 2008-06-24 | 2013-11-29 | Sanofi Sa | Isoquinolinas e isoquinolinonas 6-substituídas |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| US20120202793A1 (en) * | 2009-03-09 | 2012-08-09 | Paul Sweetnam | Rho kinase inhibitors |
| EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| EP2611793A1 (en) | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
| TWI674262B (zh) * | 2011-01-10 | 2019-10-11 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| EP2970172B1 (en) * | 2013-03-14 | 2019-10-30 | Bristol-Myers Squibb Company | Bicyclo [2.2.2]acid gpr120 modulators |
| KR102243637B1 (ko) | 2013-03-14 | 2021-04-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | 바이사이클릭 진통 화합물 |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
| DK3811943T3 (da) | 2013-03-15 | 2023-04-03 | Aerie Pharmaceuticals Inc | Forbindelse til anvendelse til behandling af øjenlidelser |
| EP3290407B1 (en) | 2013-10-18 | 2020-01-01 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
| CN108947867A (zh) | 2013-12-12 | 2018-12-07 | 卡利拉制药公司 | 双环烷基化合物及合成 |
| FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2942144C (en) | 2014-03-07 | 2023-08-22 | Kalyra Pharmaceuticals, Inc. | Propellane derivates and synthesis |
| MA38393B1 (fr) * | 2014-03-13 | 2018-11-30 | Sanofi Sa | Composés hétéroaryle et utilisations associées |
| CN106999451B (zh) | 2014-09-17 | 2021-04-02 | 里科瑞尔姆Ip控股有限责任公司 | 双环化合物 |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10550087B2 (en) | 2015-11-17 | 2020-02-04 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| US20190060257A1 (en) * | 2016-03-16 | 2019-02-28 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
| AU2017252276A1 (en) | 2016-04-18 | 2018-11-15 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
| KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
| EP3628043A4 (en) | 2017-05-15 | 2021-04-28 | Recurium IP Holdings, LLC | ANALGESIC COMPOUNDS |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| CN117337267A (zh) * | 2021-04-05 | 2024-01-02 | 达纳－法伯癌症研究所公司 | 适用于点击/取消点击应用的生物正交反应 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1541559A1 (en) * | 2002-07-22 | 2005-06-15 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| HU178522B (en) * | 1979-04-11 | 1982-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing amino-isoquinoline derivatives |
| JPH06501921A (ja) | 1990-07-31 | 1994-03-03 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 選択されたハロカーボンの触媒平衡化 |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| NZ513800A (en) | 1996-08-12 | 2001-09-28 | Welfide Corp | Treatment of diseases using Rho kinase inhibitors |
| JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
| JP2001514259A (ja) | 1997-08-29 | 2001-09-11 | ゼネカ・リミテッド | アミノメチルオキソオキサゾリジニルベンゼン誘導体 |
| TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
| US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
| IL150650A0 (en) | 2000-01-20 | 2003-02-12 | Eisai Co Ltd | Piperidine derivatives and pharmaceutical compositions containing the same |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| WO2001064238A2 (en) | 2000-02-29 | 2001-09-07 | Curis, Inc. | Methods and compositions for regulating adipocytes |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| CN1441784A (zh) * | 2000-07-12 | 2003-09-10 | 阿克佐诺贝尔公司 | 含有氨基异喹啉基团的凝血酶抑制剂 |
| WO2002034712A1 (en) | 2000-10-27 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
| WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Ｒｈｏキナーゼ阻害剤 |
| GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
| WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| EP1550660A1 (en) | 2002-09-12 | 2005-07-06 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| WO2004105757A2 (en) | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| EP1638939A2 (en) | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| JP4794446B2 (ja) | 2003-09-23 | 2011-10-19 | メルク・シャープ・エンド・ドーム・コーポレイション | イソキノリン系カリウムチャンネル阻害薬 |
| WO2005030791A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Isoquinolinone potassium channel inhibitors |
| US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
| JPWO2005035516A1 (ja) | 2003-10-10 | 2006-12-21 | 小野薬品工業株式会社 | 新規縮合複素環化合物およびその用途 |
| WO2005054202A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| JP2005232175A (ja) * | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | ５−置換イソキノリン医薬 |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| EP1729761A4 (en) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| KR101373535B1 (ko) | 2005-07-26 | 2014-03-12 | 사노피 | Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체 |
| JP5049970B2 (ja) | 2005-07-26 | 2012-10-17 | サノフイ | Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体 |
| TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
| US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
| TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
| WO2008077555A2 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinolines and their use as rho-kinase inhibitors |
| RU2468011C2 (ru) | 2006-12-27 | 2012-11-27 | Санофи-Авентис | Замещенные циклоалкиламином производные изохинолина и изохинолинона |
-
2007
- 2007-12-19 RU RU2009128652/04A patent/RU2468011C2/ru not_active IP Right Cessation
- 2007-12-19 DE DE602007010981T patent/DE602007010981D1/de active Active
- 2007-12-19 NZ NZ577984A patent/NZ577984A/en not_active IP Right Cessation
- 2007-12-19 ES ES07856892T patent/ES2355534T3/es active Active
- 2007-12-19 KR KR1020097013327A patent/KR101494452B1/ko not_active Expired - Fee Related
- 2007-12-19 PT PT07856892T patent/PT2102164E/pt unknown
- 2007-12-19 CA CA2673922A patent/CA2673922C/en not_active Expired - Fee Related
- 2007-12-19 SI SI200730505T patent/SI2102164T1/sl unknown
- 2007-12-19 WO PCT/EP2007/011169 patent/WO2008077556A1/en not_active Ceased
- 2007-12-19 HR HR20100705T patent/HRP20100705T1/hr unknown
- 2007-12-19 CN CN2007800484652A patent/CN101578266B/zh not_active Expired - Fee Related
- 2007-12-19 RS RS20110096A patent/RS51655B/sr unknown
- 2007-12-19 BR BRPI0720859-6A patent/BRPI0720859A2/pt not_active IP Right Cessation
- 2007-12-19 MY MYPI20092206A patent/MY154767A/en unknown
- 2007-12-19 AT AT07856892T patent/ATE490243T1/de active
- 2007-12-19 PL PL07856892T patent/PL2102164T3/pl unknown
- 2007-12-19 AU AU2007338412A patent/AU2007338412B2/en not_active Ceased
- 2007-12-19 MX MX2009005967A patent/MX2009005967A/es active IP Right Grant
- 2007-12-19 EP EP07856892A patent/EP2102164B1/en active Active
- 2007-12-19 DK DK07856892.0T patent/DK2102164T3/da active
- 2007-12-19 JP JP2009543377A patent/JP5318779B2/ja not_active Expired - Fee Related
- 2007-12-25 TW TW096149807A patent/TWI423803B/zh not_active IP Right Cessation
- 2007-12-26 AR ARP070105898A patent/AR064531A1/es unknown
- 2007-12-26 CL CL200703820A patent/CL2007003820A1/es unknown
- 2007-12-26 UY UY30845A patent/UY30845A1/es unknown
-
2009
- 2009-05-20 CR CR10811A patent/CR10811A/es not_active Application Discontinuation
- 2009-05-22 ZA ZA200903555A patent/ZA200903555B/xx unknown
- 2009-06-04 NI NI200900111A patent/NI200900111A/es unknown
- 2009-06-12 CO CO09061604A patent/CO6210815A2/es active IP Right Grant
- 2009-06-18 US US12/487,503 patent/US8710077B2/en not_active Expired - Fee Related
- 2009-06-23 SV SV2009003314A patent/SV2009003314A/es unknown
- 2009-06-24 MA MA32040A patent/MA31076B1/fr unknown
- 2009-06-26 GT GT200900183A patent/GT200900183A/es unknown
- 2009-06-26 TN TNP2009000274A patent/TN2009000274A1/fr unknown
- 2009-06-26 EC EC2009009468A patent/ECSP099468A/es unknown
- 2009-07-01 NO NO20092488A patent/NO20092488L/no not_active Application Discontinuation
-
2011
- 2011-02-04 CY CY20111100131T patent/CY1111323T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1541559A1 (en) * | 2002-07-22 | 2005-06-15 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
Non-Patent Citations (3)
| Title |
|---|
| Atsuya Takami et al.Design and synthesis of Rho kinase inhibitors (I).《Bioorganic & Medicinal Chemistry》.2004,2115–2137. * |
| Masayuki Iwakubo et al.Design and synthesis of Rho kinase inhibitors (II).《Bioorganic & Medicinal Chemistry》.2006,350–364. * |
| Masayuki Iwakubo et al.Design and synthesis of rho kinase inhibitors (III).《Bioorganic & Medicinal Chemistry》.2006,1022–1033. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101578266B (zh) | 环烷基胺取代的异喹啉和异喹啉酮衍生物 | |
| CN101595094B (zh) | 环烷基胺取代的异喹诺酮衍生物 | |
| CN101573353A (zh) | 取代的异喹啉和异喹啉酮衍生物 | |
| CN101228132A (zh) | 作为Rho-激酶抑制剂的环己基胺异喹啉酮衍生物 | |
| CN101228149A (zh) | 作为Rho-激酶抑制剂的哌啶基取代的异喹啉酮衍生物 | |
| JP5313919B2 (ja) | 新規な置換イソキノリン及びイソキノリノン誘導体 | |
| KR101638326B1 (ko) | Ｒｈｏ 키나제 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논 | |
| CN101573338A (zh) | 环烷基胺取代的异喹诺酮和异喹啉酮衍生物 | |
| TW202325301A (zh) | 三環稠雜環類pde3/4雙重抑制及其用途 | |
| CN105473575A (zh) | 作为alx受体激动剂的苯并咪唑基-甲基脲衍生物 | |
| JP2010517958A (ja) | ＰＤＥ５インヒビターとして有用な６−ベンジル−２，３，４，７−テトラヒドロ−インドロ［２，３−ｃ］キノリン化合物 | |
| JP2024506182A (ja) | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 | |
| CN102131785B (zh) | 6-取代的异喹啉和异喹啉酮 | |
| CN102076667B (zh) | 二环和多环取代的异喹啉和异喹啉酮衍生物 | |
| HK1138585B (en) | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | |
| HK1139390B (en) | Cycloalkylamine substituted isoquinolone derivatives | |
| HK1123036B (en) | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors | |
| HK1123035B (en) | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1138585 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1138585 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131030 Termination date: 20181219 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |